Skip to main content

Drug Interactions between rizatriptan and Zomig-ZMT

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

ZOLMitriptan rizatriptan

Applies to: Zomig-ZMT (zolmitriptan) and rizatriptan

CONTRAINDICATED: Coadministration of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications may potentiate the risk of vasospastic reactions, including coronary artery vasospasm, peripheral vascular ischemia and colonic ischemia, due to additive pharmacologic effects. Acute myocardial infarction due to sustained vasospasm occurred in a premenopausal woman with controlled hypertension and no known history of coronary artery disease following two 2 mg doses of methysergide maleate 12 hours apart and a subcutaneous injection of sumatriptan 6 mg.

MANAGEMENT: The concomitant use of two or more 5-HT1 receptor agonists and/or ergotamine-containing or ergot-type medications, or use within 24 hours of each other, is considered contraindicated.

References (9)
  1. (2001) "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome
  2. (2001) "Product Information. Parlodel (bromocriptine)." Sandoz Pharmaceuticals Corporation
  3. (2001) "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals
  4. (2001) "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals
  5. (2001) "Product Information. Amerge (naratriptan)." Glaxo Wellcome
  6. (2001) "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc
  7. (2001) "Product Information. Axert (almotriptan)." Pharmacia and Upjohn
  8. Liston H, Bennett L, Usher B, Nappi J (1999) "The association of the combination of sumatriptan and methysergide in myocardial infarction in a premenopausal woman." Arch Intern Med, 159, p. 511-3
  9. (2003) "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals

Drug and food interactions

Moderate

ZOLMitriptan food

Applies to: Zomig-ZMT (zolmitriptan)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (4)
  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Sympatholytics

Therapeutic duplication

The recommended maximum number of medicines in the 'sympatholytics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'sympatholytics' category:

  • rizatriptan
  • Zomig-ZMT (zolmitriptan)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

Duplication

Ergot-like drugs

Therapeutic duplication

The recommended maximum number of medicines in the 'ergot-like drugs' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'ergot-like drugs' category:

  • rizatriptan
  • Zomig-ZMT (zolmitriptan)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer